Wegovy 1.7mg: the dose between starter and maintenance

Why 1.7mg exists in the schedule rather than jumping straight to 2.4mg

The Wegovy titration pathway is not a one-size-fits-all dose ladder climbed as fast as possible. Each step up increases the amount of semaglutide your system processes, and the slower the ascent the fewer side effects most people experience. The jump from 1mg directly to 2.4mg would, for many, produce significant nausea or vomiting; 1.7mg bridges that gap.

Think of it less as a halfway house and more as a calibration point. Your prescriber is watching how you tolerated 1mg before authorising the move. If GI symptoms were heavy at 1mg, staying at 1.7mg for a little longer (rather than pushing straight to maintenance) is a legitimate clinical decision. The semaglutide overview explains the mechanism behind all of this in more detail, but the short version is that the drug slows stomach emptying, and your gut needs time to adapt to each new level.

The NHS medicines information on semaglutide confirms that the full titration schedule, including the 1.7mg step, is part of the licensed UK use of Wegovy, it is not optional or advisory. Skipping steps is a deviation from the licensed schedule and something your prescriber will not recommend without good clinical reason. NHS guidance on semaglutide covers what each stage of treatment involves at a patient level.

What to expect at 1.7mg compared with earlier doses

If you sailed through 0.25mg and 0.5mg with minimal side effects, 1.7mg may catch you off guard. It is the largest single percentage increase in dose on the whole schedule (moving from 1mg to 1.7mg is a 70% jump in semaglutide per injection) and the GI system often registers the change.

Nausea is the most commonly reported effect at this step, sometimes accompanied by constipation or loose stools, burping, or a sharper sense of fullness after small portions. For most people these effects are at their worst in the first week or two at 1.7mg and then ease. Eating slowly, avoiding very fatty meals, and staying well hydrated all help. Details on managing specific symptoms sit on our Wegovy side effects page, which covers the more serious signs that warrant medical attention.

Appetite suppression at 1.7mg is noticeably stronger than at 1mg for many people, this is usually the first dose at which patients report feeling genuinely indifferent to portions they would previously have finished without thinking. That shift is clinical progress, not a sign something is wrong. It can, though, make it harder to eat enough protein and fibre; both matter for preserving muscle while losing weight, so keep that in mind as appetite drops further.

If you are curious about how the 1.7mg experience differs from being at week seven specifically, the Wegovy week seven page covers the timeline in more practical terms.

The eligibility and clinical picture that surround this dose

Reaching 1.7mg does not mean you have earned it automatically. Your prescriber reviews your progress (weight change, side-effect tolerance, any new health information) before each dose step. For private treatment through a regulated online pharmacy, this review happens before every repeat supply; it is not a formality.

The licensed criteria for Wegovy in the UK are a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as raised blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. These criteria apply from the start of treatment, but they also frame ongoing prescribing: if a patient is not tolerating any dose well enough to continue, the prescriber's role is to advise on whether to pause, stay at a lower dose, or stop.

On the NHS, Wegovy is available through specialist weight management services under NICE guidance, NICE technology appraisal TA875 sets out the eligibility criteria, including the requirement for multidisciplinary specialist care and a maximum treatment duration of two years. Waiting lists for those services can be long. Private treatment through a GPhC-registered pharmacy is the alternative route for people who meet the licensed criteria but cannot access NHS provision quickly.

Thinking about the cost of Wegovy treatment is a reasonable part of the decision at this point; prices vary by dose, and understanding what is included in any quoted price matters as much as the headline figure.

What 1.7mg means for your trajectory toward 2.4mg

One honest thing worth saying: a lot of people arrive at 1.7mg feeling cautiously optimistic but slightly anxious about whether they will tolerate 2.4mg, or whether 1.7mg is doing enough. Both are fair things to wonder about.

The evidence base for Wegovy's results comes primarily from 2.4mg, the STEP 1 trial, published in the New England Journal of Medicine, reported an average weight loss of around 15% over 68 weeks at the 2.4mg maintenance dose. Most participants spent only a fraction of that time at 1.7mg. So if your results at 1.7mg feel modest, that is not unexpected: this is a transitional dose, not a destination. The MHRA has since approved a higher 7.2mg dose for adults with a BMI of 30 or above; the dedicated Wegovy 7.2mg pen page covers that development for those who want the full picture on where the medicine is heading.

If your prescriber has confirmed you are on track to move to 2.4mg, the Wegovy 1mg page gives useful context on how the earlier steps compare. And if you are weighing up whether Wegovy is the right medicine for you at all, our weight-loss treatment overview lays out the full licensed options side by side.

Ready to talk to a prescriber about whether you are eligible? Check your eligibility with a free consultation, a GPhC-registered prescriber reads every submission the same day.